# Vericel Corp (VCEL)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/vericel-corp/ JSON: https://steadybase.io/company/vericel-corp.json Checked Nov 10, 2026. Latest filing read: Nov 5, 2026.

## Company

- Legal name: Vericel Corp
- Ticker: VCEL (Nasdaq)
- SEC CIK: 0000887359
- Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
- Headquarters: Burlington, MA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: vcel.com
- LinkedIn: https://www.linkedin.com/company/vericel-corporation
- Next earnings date: Jan 8, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $276.3M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/887359/000162828026012013/0001628280-26-012013-index.html
- Operating income: $11.0M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/887359/000162828026012013/0001628280-26-012013-index.html
- Net income: $16.5M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/887359/000162828026012013/0001628280-26-012013-index.html
- SG&A: $167.0M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/887359/000162828026012013/0001628280-26-012013-index.html
- Employees: 398 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/887359/000162828026012013/vcel-20251231.htm
- Shares outstanding: 51,029,770 as of Oct 29, 2026 (10-Q filed Nov 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/887359/000162828026070657/0001628280-26-070657-index.html
- Auditor: Pricewaterhousecoopers LLP, Boston, Massachusetts, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/887359/000162828026012013/vcel-20251231.htm

## Business

Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. We have a highly differentiated portfolio of cell therapy and specialty biologic products that combines innovations in biology with medical technologies. We were among the first companies to achieve commercial success in the complex field of cell therapies with treatments that use tissue engineering to regenerate skin and healthy knee cartilage.S.S.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/887359/000162828026012013/vcel-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $276.3M | $11.0M | $16.5M | $167.0M |
| Dec 31, 2024 | $237.2M | $4.5M | $10.4M | $142.8M |
| Dec 31, 2023 | $197.5M | -$6.5M | -$3.2M | $121.0M |
| Dec 31, 2022 | $164.4M | -$17.1M | -$16.7M | $106.9M |
| Dec 31, 2021 | $156.2M | -$7.9M | -$7.5M | $97.6M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/vericel-corp.json

## Officers and directors

- Dominick Colangelo, President and CEO. Source: Form 4 filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/887359/000114036126006974/0001140361-26-006974-index.htm
- Joseph Anthony Mara Jr, Chief Financial Officer. LinkedIn: https://linkedin.com/in/joe-mara-2389786. Source: Form 4 filed Jun 30, 2026, https://www.sec.gov/Archives/edgar/data/887359/000114036126026931/0001140361-26-026931-index.htm
- Joseph Mara, Chief Financial Officer. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/887359/000162828026012013/vcel-20251231.htm
- Michael Halpin, Chief Operating Officer. LinkedIn: https://linkedin.com/in/michael-halpin-66420a6. Source: Form 4 filed Aug 5, 2026, https://www.sec.gov/Archives/edgar/data/887359/000114036126031417/0001140361-26-031417-index.htm
- Jonathan Siegal, Principal Accounting Officer. Source: Form 4 filed Jul 31, 2026, https://www.sec.gov/Archives/edgar/data/887359/000114036126030487/0001140361-26-030487-index.htm
- Jonathan Mark Hopper, Chief Medical Officer. Source: Form 4 filed Jun 30, 2026, https://www.sec.gov/Archives/edgar/data/887359/000114036126026930/0001140361-26-026930-index.htm
- Sean C. Flynn, Chief Legal Officer. Source: Form 4 filed Jun 30, 2026, https://www.sec.gov/Archives/edgar/data/887359/000114036126026929/0001140361-26-026929-index.htm
- Sean Flynn, Chief Legal Officer. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/887359/000162828026012013/vcel-20251231.htm
- Karen Mahoney, Chief Human Resources Officer. LinkedIn: https://linkedin.com/in/karen-a-mahoney. Source: Form 4 filed Dec 12, 2025, https://www.sec.gov/Archives/edgar/data/887359/000114036125045382/0001140361-25-045382-index.htm
- Heidi Hagen, member of the Vericel Corporation Board of Directors. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/887359/000162828026012013/vcel-20251231.htm
- Joe Mara, Board member (per proxy). LinkedIn: https://www.linkedin.com/in/joe-mara-2389786. Source: DEF 14A filed Mar 19, 2026, https://www.sec.gov/Archives/edgar/data/887359/000130817926000094/vcel2026_def14a.htm

## Recent 8-K events

- Nov 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/887359/000162828026070622/vcel-20261105.htm
- Jul 30, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/887359/000162828026050815/vcel-20260730.htm
- May 18, 2026: Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126021892/ef20073865_8k.htm
- May 7, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/887359/000162828026031713/vcel-20260507.htm
- May 1, 2026: Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126018538/ef20071924_8k.htm
- Feb 26, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/887359/000162828026012003/vcel-20260226.htm
- Jan 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126001060/ef20062769_8k.htm
- Nov 6, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/887359/000162828025049880/vcel-20251106.htm
- Jul 31, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/887359/000162828025036854/vcel-20250731.htm
- May 8, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/887359/000162828025023481/vcel-20250508.htm

## Insider trades (Form 4)

- Nov 6, 2026: Joseph Anthony Mara Jr (Chief Financial Officer) sold 50,000 shares, about $2.7M. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126042785/0001140361-26-042785-index.htm
- Nov 5, 2026: Sean C. Flynn (Chief Legal Officer) sold 15,000 shares, about $778,800. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126042464/0001140361-26-042464-index.htm
- Nov 5, 2026: Jonathan Siegal (Principal Accounting Officer) sold 1,500 shares, about $79,350. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126042463/0001140361-26-042463-index.htm
- Nov 5, 2026: Robert L. Zerbe Md (Director) sold 5,500 shares, about $270,175. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126042462/0001140361-26-042462-index.htm
- Aug 12, 2026: Kevin F. Mclaughlin (Director) sold 7,000 shares, about $311,710. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126033143/0001140361-26-033143-index.htm
- Aug 3, 2026: Michael Halpin (Chief Operating Officer) sold 10,000 shares, about $468,400. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126031417/0001140361-26-031417-index.htm
- Jul 30, 2026: Jonathan Siegal (Principal Accounting Officer) sold 4,500 shares, about $220,050. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126030487/0001140361-26-030487-index.htm
- Jun 26, 2026: Jonathan Siegal (Principal Accounting Officer) sold 2,732 shares, about $122,667. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126026932/0001140361-26-026932-index.htm
- Jun 26, 2026: Joseph Anthony Mara Jr (Chief Financial Officer) sold 5,000 shares, about $223,750. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126026931/0001140361-26-026931-index.htm
- Jun 26, 2026: Jonathan Mark Hopper (Chief Medical Officer) sold 10,000 shares, about $450,000. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126026930/0001140361-26-026930-index.htm
- Jun 26, 2026: Sean C. Flynn (Chief Legal Officer) sold 15,000 shares, about $684,600. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126026929/0001140361-26-026929-index.htm
- Jun 18, 2026: Michael Halpin (Chief Operating Officer) sold 10,000 shares, about $402,400. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126025952/0001140361-26-025952-index.htm
- Jun 18, 2026: Sean C. Flynn (Chief Legal Officer) sold 15,000 shares, about $603,150. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126025951/0001140361-26-025951-index.htm
- Jun 2, 2026: Jonathan Mark Hopper (Chief Medical Officer) sold 4,375 shares, about $153,125. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126023988/0001140361-26-023988-index.htm
- May 13, 2026: Kevin F. Mclaughlin (Director) sold 7,000 shares, about $229,775. Source: https://www.sec.gov/Archives/edgar/data/887359/000114036126021656/0001140361-26-021656-index.htm

## What management said

- "The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow, while also returning capital to shareholders" Nick Colangelo, President and CEO of Vericel (8-K filed Nov 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/887359/000162828026070622/ex991earningsreleaseq32026.htm

## Latest filings

- 8-K filed Jul 30, 2026: https://www.sec.gov/Archives/edgar/data/887359/000162828026050815/vcel-20260730.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/887359/000162828026012013/vcel-20251231.htm
- 10-Q filed Jul 30, 2026: https://www.sec.gov/Archives/edgar/data/887359/000162828026050836/vcel-20260630.htm
- DEF 14A filed Mar 19, 2026: https://www.sec.gov/Archives/edgar/data/887359/000130817926000094/vcel2026_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/